Cushing, Victoria I. http://orcid.org/0000-0002-7976-0859
Koh, Adrian F. http://orcid.org/0000-0001-6682-4449
Feng, Junjie
Jurgaityte, Kaste http://orcid.org/0009-0004-4356-6677
Bondke, Alexander
Kroll, Sebastian H. B.
Barbazanges, Marion http://orcid.org/0000-0002-1511-6538
Scheiper, Bodo
Bahl, Ash K.
Barrett, Anthony G. M. http://orcid.org/0000-0002-8485-215X
Ali, Simak http://orcid.org/0000-0002-1320-0816
Kotecha, Abhay http://orcid.org/0000-0002-4480-5439
Greber, Basil J. http://orcid.org/0000-0001-9379-7159
Funding for this research was provided by:
RCUK | Medical Research Council (MR/V009354/1)
Cancer Research UK (C37/A9335, C37/A12011, C37/A18784)
Article History
Received: 4 July 2023
Accepted: 23 February 2024
First Online: 13 March 2024
Competing interests
: A.K. and A.F.K are employees of Thermo Fisher Scientific, the manufacturer of the electron microscopes used in this study. S.A., A.G.M.B, and A.B. are named inventors on patents concerning CDK7 inhibitors, which have been licensed to Carrick Therapeutics (U.S. patents US 9932344 B2, US 8067424 B2, US11857552 B2, US8507673 B2). They have received milestone payments from the patent licensing, and own shares in Carrick Therapeutics. S.A. has received research funding and reagents from Carrick Therapeutics. S.A. has also received research funding from Astra Zeneca. S.H.B.K. and B.S. are named inventors on patents concerning CDK7 inhibitors, which have been licensed to Carrick Therapeutics (U.S. patents US 9932344 B2, US 8067424 B2, US11857552 B2, US8507673 B2). They have received milestone payments from the patent licensing. M.B. has received milestone payments from the patent licensing. A.K.B. is an employee and shareholder of Carrick Therapeutics. All other authors declare no competing interests.